The field of pharmacogenomics has experienced unprecedented progress in the last decade, mainly due, but not limited to, the implementation of sophisticated laboratory methodologies and the use of bioinformatical approaches which allowed a better interpretation of omic data. Nevertheless, the translational value of pharmacogenomics of medications used in neuropsychiatric disorders is still hampered by our limited knowledge of their mechanism of action and by the phenotypic and biological complexity of the phenotype. Overall, findings suggest that the efforts put into place so far have paved the path towards better management of pharmacological treatments for these disorders, and support the value of integrated molecular approaches for the identification of reliable biomarkers of response.
It has become clear that personalized medicine in neuropsychiatric disorders can be achieved only if different sources of molecular data, produced in the preclinical and clinical setting, are analyzed and interpreted in a framework including environmental features. This Research Topic aims to provide an overview of the different approaches applied to explore the pharmacogenomics of medications used in neuropsychiatric disorders, ranging from preclinical to clinical studies.
For this Research Topic, we welcome especially Original Research and Review articles on the different aspects of the pharmacogenomics of medications used to treat neuropsychiatric disorders, including, but not limited to:
- Studies exploring or reviewing the role of biological systems, either in patients, human-derived cell lines, or animal models.
- Studies implementing statistical approaches to better exploit the large amount of genetic data produced by the pharmacogenomic studies in this field.
Topic Editor Dr Ramon Cacabelos is the President and stockholder of EuroEspes SA. All other Topic Editors declare no competing interests with regards to the Research Topic subject.
The field of pharmacogenomics has experienced unprecedented progress in the last decade, mainly due, but not limited to, the implementation of sophisticated laboratory methodologies and the use of bioinformatical approaches which allowed a better interpretation of omic data. Nevertheless, the translational value of pharmacogenomics of medications used in neuropsychiatric disorders is still hampered by our limited knowledge of their mechanism of action and by the phenotypic and biological complexity of the phenotype. Overall, findings suggest that the efforts put into place so far have paved the path towards better management of pharmacological treatments for these disorders, and support the value of integrated molecular approaches for the identification of reliable biomarkers of response.
It has become clear that personalized medicine in neuropsychiatric disorders can be achieved only if different sources of molecular data, produced in the preclinical and clinical setting, are analyzed and interpreted in a framework including environmental features. This Research Topic aims to provide an overview of the different approaches applied to explore the pharmacogenomics of medications used in neuropsychiatric disorders, ranging from preclinical to clinical studies.
For this Research Topic, we welcome especially Original Research and Review articles on the different aspects of the pharmacogenomics of medications used to treat neuropsychiatric disorders, including, but not limited to:
- Studies exploring or reviewing the role of biological systems, either in patients, human-derived cell lines, or animal models.
- Studies implementing statistical approaches to better exploit the large amount of genetic data produced by the pharmacogenomic studies in this field.
Topic Editor Dr Ramon Cacabelos is the President and stockholder of EuroEspes SA. All other Topic Editors declare no competing interests with regards to the Research Topic subject.
